Retatrutide (Eli Lilly's experimental triple agonist of GLP-1, GIP, and glucagon receptors) is generating headlines because the phase 2 TRIUMPH-1 data showed average weight loss of around 24% at 48 weeks — higher than tirzepatide or semaglutide has reported. Australian patients are now asking GPs and telehealth doctors for retatrutide directly. In nearly every case in 2026, the clinically appropriate answer is still tirzepatide. Here is why.
Mechanism: tirzepatide hits two receptors — GLP-1 and GIP. Retatrutide hits three — GLP-1, GIP, and glucagon. The glucagon-receptor component is thought to increase basal energy expenditure on top of appetite suppression and insulin sensitisation. Mechanistically, retatrutide is a step beyond tirzepatide. But mechanism is not evidence and mechanism is not approval.
Regulatory status in Australia: tirzepatide is ARTG-registered as Mounjaro. It is prescribed on a standard private script and dispensed from any Australian pharmacy. Retatrutide is not ARTG-registered. It is in phase 3 trials. The only lawful Australian access pathway is via a TGA Special Access Scheme Category B notification — a per-patient case lodged by an AHPRA-registered doctor — and dispensing through a TGA-licensed compounding pharmacy. Most prescribers will not lodge that SAS-B notification while an ARTG-registered alternative exists, because the professional bar for "clinical justification" is high and ARTG-approval is a strong default.
Evidence: tirzepatide has multi-year published outcomes data including SURMOUNT-1 (72-week weight management) and SURPASS (T2D glycaemic control). Long-term cardiovascular and renal outcomes are accumulating. Retatrutide has phase 2 (TRIUMPH-1) at 48 weeks plus ongoing phase 3 readouts. The published evidence base is roughly an order of magnitude smaller and shorter. For a chronic-use drug taken for months or years, that gap matters.
Free guide: Legal Peptides in Australia (2026)
What's legal under TGA SAS-B, which peptides Australian doctors actually prescribe, real costs, and the questions to ask at your consult.
No spam. Unsubscribe any time. See our privacy policy.
Safety: both share the standard incretin-class side effect profile during titration (nausea, reflux, constipation, decreased appetite) and the same contraindications (MTC/MEN-2 history, prior pancreatitis, pregnancy, breastfeeding). Retatrutide's glucagon-receptor activity adds theoretical effects on glucose handling and heart rate that are still being characterised in phase 3. Until phase 3 reads out, an Australian prescriber managing a long-term weight-management case has a clean clinical reason to prefer the molecule with the better-understood long-term profile.
Cost in Australia (2026): Mounjaro runs roughly AUD $400–$650 per month on a private script depending on dose. Compounded retatrutide via SAS-B, where it is prescribed at all, typically sits in the AUD $400–$700 range — not cheaper, sometimes more expensive, and without the supply-chain confidence of an ARTG-registered product.
So when would an Australian doctor actually consider retatrutide? Realistically, after a patient has trialled tirzepatide (and ideally semaglutide), has tolerated the class, has plateaued or under-responded, and has no clinical reason to avoid glucagon-receptor activation. Even then, the prescriber has to be comfortable lodging an SAS-B notification on a phase-3 molecule. Most AHPRA-registered prescribers in 2026 will say "let's optimise your tirzepatide titration first" before going there — and that is a defensible clinical position.
What you absolutely should not do is buy "retatrutide" from a .com.au website that ships from offshore. Those sellers are not AHPRA-registered prescribers and not TGA-licensed compounding pharmacies. The vial they ship has no validated identity, potency, or sterility — and you, the buyer, carry the legal exposure under state Poisons Acts and the Customs Act. Australian Border Force routinely seizes parcels.
If you want a 2026 starting point in Australia, the question is not "tirzepatide or retatrutide". It is "tirzepatide or semaglutide" — both ARTG-registered, both with long-term outcomes data, both dispensed from regular Australian pharmacies. Retatrutide is a 2027–2028 conversation for most patients.